Floatz logo

Talzenna

Clinical Stage III Gastric Cancer AJCC v8

National Cancer Institute (NCI)Phase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

282 Active assets in the Clinical Stage III Gastric Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Rivoceranib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4BBB
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 4BB
Eloxatin
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Docetaxel
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3BB
Cyclophosphamide
Vall d'Hebron Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Talzenna is also rated in:

BRCA2-related cancer predispositionDormant
BB
Indicative ·
68 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →